Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease | Canada Hyperbarics Skip to main content
Case Report Future Sci OA 2015

Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease

Agrawal G, Borody T, Turner R, Leis S, Campbell J — Future Sci OA, 2015

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers treated nine patients with difficult-to-heal Crohn's disease fistulas using a combination of infliximab, 18-30 sessions of hyperbaric oxygen therapy, and anti-MAP antibiotics.

What They Found

All nine patients (100%) experienced complete healing of their fistulas. This healing occurred within 6 to 28 weeks, and patients were followed for an average of 18 months.

What This Means for Canadian Patients

For Canadian patients with Crohn's disease who have fistulas that don't respond to standard treatments, this study suggests a new combination therapy might offer hope. This approach, including hyperbaric oxygen therapy, could help heal these challenging fistulas and improve quality of life.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The main limitation of this study is its small size, as it only involved nine patients in a case series.

Was this summary helpful?

Study Details

Study Type Case Report
Category Wound Care
Source Pubmed
PubMed ID 28031926
Year Published 2015
Journal Future Sci OA

Cite This Study

Share

Find a Canadian Clinic Treating Wound Care

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.